Related Experiment Video
Updated: May 21, 2026
06:59
Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation
Published on: June 3, 2018
Cerebral Embolic Protection During Transcatheter Aortic Valve Implantation: A Meta-Analysis, Meta-Regression, and
Farhan Naeem1, Usama Qamar2, Muhammad Burhan3
1From the Department of Cardiology, Massachusetts General Hospital, Boston, MA.
Cardiology in Review
|May 20, 2026
Summary
Cerebral embolic protection devices (CEPDs) do not significantly reduce stroke or cognitive decline after transcatheter aortic valve implantation (TAVI). This meta-analysis suggests limited support for routine CEPD use in TAVI procedures.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- Stroke is a significant complication following transcatheter aortic valve implantation (TAVI).
- Cerebral embolic protection devices (CEPDs) aim to mitigate periprocedural embolization during TAVI.
- The clinical effectiveness of CEPDs in preventing stroke and cognitive decline post-TAVI remains uncertain.
Purpose of the Study:
- To systematically review and meta-analyze the efficacy of CEPDs in reducing stroke and cognitive decline after TAVI.
- To evaluate the impact of CEPDs on various clinical outcomes, including stroke, ischemic lesions, cognitive function, and safety events.
Main Methods:
- Systematic review and meta-analysis of 8 randomized controlled trials involving 11,775 patients undergoing TAVI.
- Primary outcomes included any stroke, disabling stroke, non-disabling stroke, new ischemic lesions, and cognitive decline (Montreal Cognitive Assessment, National Institutes of Health Stroke Scale).
- Secondary outcomes assessed mortality, bleeding, vascular complications, and acute kidney injury. Random-effects models and trial sequential analyses were employed.
Main Results:
- CEPDs did not significantly reduce the incidence of any stroke (RR: 0.92), disabling stroke (RR: 0.80), or non-disabling stroke (RR: 1.08).
- No significant differences were found in new ischemic lesion counts, National Institutes of Health Stroke Scale worsening, or Montreal Cognitive Assessment decline.
- The Sentinel device showed a marginal reduction in ischemic lesions without clinical benefit, and CEPD use was associated with increased major vascular complications and acute kidney injury.
Conclusions:
- CEPDs capture embolic debris but do not significantly reduce the risk of stroke or cognitive decline in patients undergoing TAVI.
- The current evidence provides limited support for the routine use of CEPDs in TAVI procedures.
- Future research should prioritize improved device design and the identification of patient subgroups who may benefit most from embolic protection.
